Susan Manzi, ACR 2021: Efficacy of Anifrolumab by Baseline Therapy in SLE
It was a pleasure to discuss with Dr Susan Manzi (Allegheny Health Network Medicine Institute, Pittsburgh, PA, USA) the recent post-hoc analysis designed to assess the efficacy of anifrolumab by baseline therapy.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials’ was presented at the ACR Convergence, 5-9 November 2021.
- What did the TULIP-1 and TULIP-2 studies teach us about the efficacy and safety of anifrolumab in people with SLE? (0:12)
- What were the objectives of the current post-hoc analysis of the TULIP-1 and TULIP-2 data? (0:56)
- What were the findings across the different therapy subgroups? (1:35)
- Could you tell us a little about the limitations of this study? (2:25)
- What are the clinical implications of these findings? (3:07)
Disclosures: Dr Susan Manzi has acted as an advisor for AstraZeneca; a consultant for Exagen Diagnostics, Inc., Cugene, GlaxoSmithKline and Eli Lilly; an officer/board member for the Lupus Foundation of America; received grant/ research support from AstraZeneca, Merck-Serono, AbbVie and GlaxoSmithKline; received royalties from Exagen Diagnostics and has intellectual properties/ patents with Exagen Diagnostics, University of Pittsburgh and the Allegheny Singer Research Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!